Warburg-Mubadala Nears $1.8B Buyout of Indian Pharma Firm Encube Ethicals

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSatyam Jha|Published at:
Warburg-Mubadala Nears $1.8B Buyout of Indian Pharma Firm Encube Ethicals
Overview

A consortium led by Warburg Pincus and Mubadala is nearing a deal to acquire a majority stake in Encube Ethicals for approximately $1.8 billion. The Mumbai-based pharmaceutical contract manufacturer is being valued at nearly 24 times its projected FY26 EBITDA, reflecting strong investor appetite for scaled CDMO businesses. Swedish firm EQT remains the other contender ahead of binding bids.

A significant private equity-backed deal is on the horizon for India's pharmaceutical manufacturing sector. The Warburg Pincus and Mubadala consortium has emerged as the frontrunner to secure a majority stake, up to 74%, in Encube Ethicals, a prominent contract development and manufacturing organization (CDMO). This potential acquisition, expected to close with binding offers next week, values the Mumbai-based firm at approximately ₹16,500 crore, or $1.8 billion.

Valuation Reflects Sector Strength

The valuation, pegged at nearly 24 times projected FY26 EBITDA, underscores the intense demand for well-established, scaled CDMO players in India. This interest is fueled by global supply chain realignments moving away from China, the strategic implications of the U.S. BioSecure Act, and India's inherent cost advantages. The sector is also benefiting from a surge in demand for complex biologics.

Deal Structure and Future Outlook

Encube Ethicals' current promoters, including founder Mehul Shah and his family, who hold about 84.2%, are poised for a significant dilution. Financial investor Quadria Capital, holding 14.9%, is expected to exit fully. The promoter group will likely retain a 15-20% stake, transitioning to a junior partner role. Management is anticipated to remain stable in the short term, with founder Mehul Shah continuing as co-promoter until a potential initial public offering (IPO) in approximately four years.

Encube Ethicals' Business

Founded in 1998, Encube Ethicals specializes in topical formulations, producing a wide array of creams, gels, and ointments for dermatology and reproductive healthcare. Its portfolio includes well-known brands such as Soframycin skin ointment.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.